✎ Contributed by Ty Griffin
- The scale and impact of cardiovascular disease underscore why innovation in this area is so critical.
- Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression.
- By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing.
Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic biomarkers to deliver actionable insights from a simple blood sample, enabling more informed and timely care cardiac care decisions.
The scale and impact of cardiovascular disease underscore why innovation in this area is so critical. According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, responsible for approximately one in every three deaths. Beyond mortality…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]